The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management
Open accessAbstract
Agents that modulate immune checkpoint proteins, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death receptor-1 (PD-1), have become a mainstay in cancer treatment. The clinical benefit afforded by immune checkpoint inhibitors can be accompanied by immune-related adverse events (irAE) that affect the skin, gastrointestinal tract, liver, and endocrine system. The types of irAEs associated with immune checkpoint inhibitors are generally consistent across tumor types. Immune-related endocrine events can affect the pituitary, thyroid, and adrenal glands, as well as other downstream target organs. These events are unique when compared with other irAEs because the manifestations are often irreversible. Immune-related endocrine events are typically grade 1/2 in severity and often present with non-specific symptoms, making them difficult to diagnose. The mechanisms underlying immune-related target organ damage in select individuals remain mostly undefined. Management includes close patient monitoring, appropriate laboratory testing for endocrine function, replacement of hormones, and consultation with an endocrinologist when appropriate. An awareness of the symptoms and management of immune-related endocrine events may aid in the safe and appropriate use of immune checkpoint inhibitors in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Textbook of Medical Physiology
(1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-6-1363_2 · Cited by 9,749
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Self-citationWeber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Self-citationTextbook of Medical Physiology
Andreiss, I. A. P., Banfíƈ, H., Barac-Latas, V., Crljen, V., Čulo, F., Ćuk, M., Dujić, Ž., Đogaš, Z., Grčević, D., Kučić, N., et al. (2006) · Cited by 1,654
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
von Mehren, M., Kane, J. M., Agulnik, M., Bui, M. M., Carr-Ascher, J., Choy, E., Connelly, M., Dry, S., Ganjoo, K. N., Gonzalez, R. J., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0035 · Cited by 1,182
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,102
Self-citationHodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30366-7 · Cited by 968
Self-citationHarding, F. A., Stickler, M. M., Razo, J., & DuBridge, R. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 737
Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.018 · Cited by 571
Faje, A. T., Sullivan, R., Lawrence, D., Tritos, N. A., Fadden, R., Klibanski, A., & Nachtigall, L. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2306 · Cited by 479
Weber, J. S., Dummer, R., de Pril, V., Lebbé, C., Hodi, F. S., & for the MDX010‐20 Investigators (2013) · Cancer · doi:10.1002/cncr.27969 · Cited by 447
Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0499 · Cited by 439
Self-citationManaging Immune Checkpoint-Blocking Antibody Side Effects
Postow, M. A. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.76 · Cited by 403
Self-citationAt the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
Callahan, M. K., & Wolchok, J. D. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212631 · Cited by 348
Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
Hughes, J., Vudattu, N., Sznol, M., Gettinger, S., Kluger, H., Lupsa, B., & Herold, K. C. (2015) · Diabetes Care · doi:10.2337/dc14-2349 · Cited by 347
Self-citationDillard, T., Yedinak, C. G., Alumkal, J., & Fleseriu, M. (2010) · Pituitary · doi:10.1007/s11102-009-0193-z · Cited by 300
Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
Maker, A. V., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Hughes, M., Yellin, M. J., Haworth, L. R., Levy, C., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000208259.73167.58 · Cited by 265
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents
Weber, J. S., Postow, M., Lao, C. D., & Schadendorf, D. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0055 · Cited by 237
Self-citationLymphocytic hypophysitis: a rare or underestimated disease?
Bellastella, A., Bizzarro, A., Coronella, C., Bellastella, G., Sinisi, A., & De Bellis, A. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490363 · Cited by 220
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
Luke, J. J., & Ott, P. A. (2015) · Oncotarget · doi:10.18632/oncotarget.2980 · Cited by 160
Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
Martín-Liberal, J., Furness, A. J. S., Joshi, K., Peggs, K. S., Quezada, S. A., & Larkin, J. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1689-1 · Cited by 137
Orlov, S., Salari, F., Kashat, L., & Walfish, P. G. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4560 · Cited by 134
Torino, F., Barnabei, A., Paragliola, R. M., Marchetti, P., Salvatori, R., & Corsello, S. M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0434 · Cited by 118
Weber, J. S., Antonia, S. J., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Liu, H. Y., Waxman, I. M., & Robert, C. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.9018 · Cited by 103
Self-citationImmune Checkpoint Inhibitor Therapy Associated Hypophysitis
Mahzari, M. M., Liu, D., Arnaout, A., & Lochnan, H. A. (2015) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s22469 · Cited by 59
Managing Immune-Related Adverse Events to Ipilimumab: A Nurse's Guide
Rubin, K. M. (2012) · Clinical journal of oncology nursing · doi:10.1188/12.cjon.e69-e75 · Cited by 21
Davies, M. J. (2016) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2016.7.5.3 · Cited by 12
Self-citation
Cited by
Immune-related adverse events of checkpoint inhibitors
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,412
A review of cancer immunotherapy toxicity
Kennedy, L. B., & Salama, A. K. S. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21596 · Cited by 1,364
Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors
Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., et al. (2018) · Diabetes · doi:10.2337/dbi18-0002 · Cited by 590
Self-citationThompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570
Self-citationEarly B cell changes predict autoimmunity following combination immune checkpoint blockade
Das, R., Bar, N., Ferreira, M., Newman, A. M., Zhang, L., Bailur, J. K., Bacchiocchi, A., Kluger, H., Wei, W., Halaban, R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96798 · Cited by 423
Self-citation
Metadata
- Authors
- Sznol, M., Postow, M. A., Davies, M. J., Pavlick, A. C., Plimack, E. R., Shaheen, M., Veloski, C., & Robert, C.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 58
- Pages
- 70-76
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2635292439
- Cited by
- 290
- References
- 38
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.